Estadístiques de Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
Visites totals
| views | |
|---|---|
| Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer | 180 |
Visites totals per mes
| views | |
|---|---|
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| isla-ceo-cost.pdf(legacy) | 274 |
| isla-ceo-cost.pdf | 113 |
Vistes principals per país
| views | |
|---|---|
| United States | 141 |
| Spain | 14 |
| Germany | 9 |
| Sweden | 6 |
| Belgium | 3 |
| Australia | 1 |
| China | 1 |
| Czechia | 1 |
| France | 1 |
| United Kingdom | 1 |
| Iran | 1 |
| Ukraine | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ashburn | 39 |
| Fairfield | 18 |
| San Ramon | 16 |
| Barcelona | 13 |
| Menlo Park | 11 |
| Boardman | 7 |
| Ann Arbor | 6 |
| Cambridge | 6 |
| Mountain View | 4 |
| Seattle | 4 |
| Fremont | 3 |
| Redwood City | 3 |
| Cupertino | 2 |
| Dearborn | 2 |
| San Mateo | 2 |
| Magdeburg | 1 |
| Phoenix | 1 |
| Premiá De Mar | 1 |
| Rochester | 1 |
| Sacramento | 1 |
| Shenzhen | 1 |